Discovery to solve multidrug resistance: Design, synthesis, and biological evaluation of novel agents. Issue 10 (23rd August 2019)
- Record Type:
- Journal Article
- Title:
- Discovery to solve multidrug resistance: Design, synthesis, and biological evaluation of novel agents. Issue 10 (23rd August 2019)
- Main Title:
- Discovery to solve multidrug resistance: Design, synthesis, and biological evaluation of novel agents
- Authors:
- Qiu, Qianqian
Shi, Wei
Zhao, Shiyuan
Zhu, Yan
Ding, Zhengquan
Zhou, Shaoyang
Kairuki, Mutta
Huang, Wenlong
Qian, Hai - Abstract:
- Abstract: Chemotherapy remains a pillar in the treatment and management of various cancers. However, multidrug resistance (MDR) becomes a severe problem after long‐term administration of chemotherapy drugs. Overexpression of P‐glycoprotein (P‐gp) is a significant cause for tumor MDR. Therefore, P‐gp inhibition is considered as an effective strategy to reverse MDR. A third‐generation P‐gp inhibitor tariquidar was selected as a lead compound, and a new series of triazol‐ N ‐ethyl tetrahydroisoquinoline based compounds were designed as novel P‐gp inhibitors and synthesized through click chemistry. These compounds presented higher reversal activities than the positive‐control verapamil (VRP). Among 18 compounds, compound11 without cytotoxicity reversed MDR in a dose‐dependent manner, with a persistent longer chemosensitizing effect and reversibility compared to others. Mechanism studies discovered that compound11 could escalate the intracellular accumulation of rhodamine‐123 and doxorubicin in K562/A02 cells as well as inhibit their efflux from cells. The results obtained suggest that compound11 is more potent than VRP administered under the same conditions; it may be a potent and safe candidate for P‐gp modulation for further development. Abstract : A new series of triazol‐ N ‐ethyl tetrahydroisoquinoline‐based compounds were synthesized through click chemistry and tested for their P‐glycoprotein (P‐gp) inhibition activity. They presented higher multidrug resistance reversalAbstract: Chemotherapy remains a pillar in the treatment and management of various cancers. However, multidrug resistance (MDR) becomes a severe problem after long‐term administration of chemotherapy drugs. Overexpression of P‐glycoprotein (P‐gp) is a significant cause for tumor MDR. Therefore, P‐gp inhibition is considered as an effective strategy to reverse MDR. A third‐generation P‐gp inhibitor tariquidar was selected as a lead compound, and a new series of triazol‐ N ‐ethyl tetrahydroisoquinoline based compounds were designed as novel P‐gp inhibitors and synthesized through click chemistry. These compounds presented higher reversal activities than the positive‐control verapamil (VRP). Among 18 compounds, compound11 without cytotoxicity reversed MDR in a dose‐dependent manner, with a persistent longer chemosensitizing effect and reversibility compared to others. Mechanism studies discovered that compound11 could escalate the intracellular accumulation of rhodamine‐123 and doxorubicin in K562/A02 cells as well as inhibit their efflux from cells. The results obtained suggest that compound11 is more potent than VRP administered under the same conditions; it may be a potent and safe candidate for P‐gp modulation for further development. Abstract : A new series of triazol‐ N ‐ethyl tetrahydroisoquinoline‐based compounds were synthesized through click chemistry and tested for their P‐glycoprotein (P‐gp) inhibition activity. They presented higher multidrug resistance reversal activities than the positive‐control verapamil. Compound11 could escalate the intracellular accumulation of rhodamine‐123 and doxorubicin in K562/A02 cells and may be used as a potent and safe candidate for P‐gp modulation for further development. … (more)
- Is Part Of:
- Archiv der Pharmazie. Volume 352:Issue 10(2019)
- Journal:
- Archiv der Pharmazie
- Issue:
- Volume 352:Issue 10(2019)
- Issue Display:
- Volume 352, Issue 10 (2019)
- Year:
- 2019
- Volume:
- 352
- Issue:
- 10
- Issue Sort Value:
- 2019-0352-0010-0000
- Page Start:
- n/a
- Page End:
- n/a
- Publication Date:
- 2019-08-23
- Subjects:
- click chemistry -- multidrug resistance -- P‐glycoprotein inhibitor -- reversal activity
Pharmaceutical chemistry -- Periodicals
Pharmacology -- Periodicals
615.19 - Journal URLs:
- http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1521-4184 ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1002/ardp.201900127 ↗
- Languages:
- English
- ISSNs:
- 0365-6233
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 1622.800000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 11855.xml